期刊论文

Xie, L.

中文

中国肿瘤临床

1000-8179

2012

39

10

674-678

10.3969/j.issn.1000-8179.2012.10.013

本文课题受国家自然科学基金项目（编号：30801335）资助

本校为第一且通讯机构

目的:探讨miR-23a与runt相关转录因子(runt-related transcription factor 1,RUNX1)在恶性淋巴瘤中的表达及临床意义。方法:运用荧光素酶报告基因活性分析检测miR-23a与RUNX1基因3'UTR区结合情况。收集150例恶性淋巴瘤及30例反应性增生淋巴组织手术标本,分别运用原位杂交、免疫组织化学方法检测两组中miR-23a、RUNX1的表达。结果:RUNX1是miR-23a直接调控的靶基因。miR-23a在150例恶性淋巴瘤组织中阳性表达率为66.7%,显著高于反应性增生淋巴组织(30.0%, P

Objective: To investigate the expression and clinical significance of miR-23a and RUNX1 in malignant lymphomas. Methods: Luciferase reporter gene activity was used to evaluate miR-23a targeting of RUNX1. A total of 150 cases with malignant lymphomas and 30 cases with lymphatic tissues with reactive hyperplasia were collected. Hybridization in situ and immunohistochemistry were used to determine the miR-23a and RUNX1 expression in the two groups, respectively. Results: MiR-23a was bound to the RUNX1 3'UTR. The positive expression rate of miR-23a was 66.7% in the malignant lymphomas, significant...